Oncology

Around one in seven people with cancer and COVID-19 report persistent symptomatic sequelae of the infection after recovery, suggest data from the OncCOVID study.

Results of the PRINCE trial point to the potential of LuPSMA plus pembrolizumab for the treatment of metastatic castration-resistant prostate cancer with high expression of PSMA.

The final overall survival findings from the MONALEESA-2 trial confirm the long-term benefits of combining ribociclib with first-line letrozole for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer.

The overall survival advantage offered by the use of durvalumab alongside first-line chemotherapy in people with extensive-stage small-cell lung cancer is sustained over time, suggests the 3-year follow-up of the CASPIAN study.

Administration of two doses of the Moderna vaccine against COVID-19 elicits an adequate immune response in most, but not all, patients with a solid tumor treated with chemotherapy, immunotherapy, or both, indicate findings.

Incorporating a drug-free interval into first-line treatment for metastatic clear cell renal cell carcinoma may not be detrimental to patient survival or quality of life, suggest STAR trial data presented at the ESMO Congress 2021.